No internet connection — showing the saved version of the page.

AIM ImmunoTech In…

USUSD
← to the screener
US:AIMLSE:0A4Y

AIM ImmunoTech Inc (LSE:0A4Y) — Biotechnology: Biological Products (No Diagnostic Substances). Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
aimimmuno.com
Investor relations
aimimmuno.com/investors/
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Headquarters
OCALA, United States
Management
Thomas K. Equels
Latest reports
quarterly 2026 · 10-Q for the period ended 2026-03-31
Employees
19
Shares outstanding
30.44 M as of 2026-08-07
Free float
27.64 M
Market cap
7.18 M USD
Insiders
0.51%
Institutions
2.88%
Industry (SIC)
Biological Products, (No Diagnostic Substances)
P/B
0.61
Debt
3.62 M USD
net cash
Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
NAV
0.27 USD
Balance sheet date30.06.2026
Assets12.7 M USD
− Liabilities4.99 M USD
= NAV (equity of the company's shareholders)7.74 M USD
− Intangible assets1.71 M USD
= Tangible NAV6.03 M USD
Shares28 990 073
NAV per share0.27 USD
Tangible NAV per share0.21 USD
NAV history
Balance sheet dateNAVNAV per share
30.06.20267.74 M USD0.27 USD
31.03.20262.13 M USD0.26 USD
31.12.2025−9.78 M USD−3.19 USD
30.09.2025−6.08 M USD−2.20 USD
30.06.2025−6.55 M USD−8.57 USD
31.03.2025−3.86 M USD−0.05 USD
31.12.2024−1.32 M USD−2.02 USD
11.12.20246.00 M USD0.20 USD
Description

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksAIM primaryUSD0.1638 +4.80%common stock
LSE London Stock Exchange0A4Y IOBGBP—common stock

Price for 3 months

up day down dayHover / tap a day — open, close, high and low prices

Top holders

HolderStakeSharesReport date
KELLNER TED D (Director)≈4.88%3.72 M2025-04-11
Jane Street Group, LLC1.06%807 8852026-06-30
MITCHELL WILLIAM M (Dire…≈0.69%522 1032025-04-11
RODINO PETER W III (Chie…≈0.53%401 7622025-04-04
APPELROUTH STEWART L. (D…≈0.51%388 7292024-12-31
BRYAN NANCY K (Director)≈0.38%291 8822025-03-14
Virtu Financial LLC0.16%124 2692026-06-30
EQUELS THOMAS K (Officer…≈0.13%102 8222026-09-16
Morgan Stanley0.07%50 8642026-06-30
Geode Capital Management…0.06%46 0032026-06-30
Fidelity Concord Street…0.06%44 0842026-07-31
Goldman Sachs Group Inc0.04%32 4442026-06-30
UBS Group AG0.04%28 9312026-06-30
CHEMEROW DAVID I (Direct…≈0.04%28 4412026-03-12
Susquehanna Internationa…0.03%21 8592026-06-30
Vanguard Fiduciary Trust…0.02%17 5192026-06-30
Ground Swell Capital, LL…0.02%12 2222026-06-30
Tower Research Capital L…0.01%4 6682026-06-30
Fidelity Concord Street…0%6822026-07-31